human tgf-β1 Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    R&D Systems recombinant human tgf β1
    Changes in ROS and GSH levels due to <t>TGF-β1-mediated</t> xCT repression. a PLC/PRF/5 ( n = 6), Huh7 ( n = 3), Huh6 ( n = 3), and HepG2 ( n = 3) cells were treated with either vehicle or 5 ng/mL of TGF-β1 for 24 h and then collected to measure GSH levels. b PLC/PRF/5 cells ( n = 3) transiently transfected with a mock- or Myc-DDK-tagged xCT-expressing vector were treated with vehicle or 5 ng/mL of TGF-β1 for 24 h and then sampled to measure GSH and protein expression levels. c PLC/PRF/5 ( n = 3) and Huh7 ( n = 3 or 6) cells transfected with a mock- or xCT-expressing vector were treated with 5 ng/mL of TGF-β1 for 24 h and then collected for ROS measurement using CM-H 2 DCFDA and western blot analysis. At 1 h before ROS measurement, 30 µM of tBHP was added to stimulate ROS generation in Huh7 cells. Overexpressed xCT was detected as having a higher molecular weight than endogenous xCT in the western blot analyses; multiple analyses are shown as the mean ± SD. * P
    Recombinant Human Tgf β1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human tgf β1/product/R&D Systems
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    recombinant human tgf β1 - by Bioz Stars, 2021-04
    86/100 stars
      Buy from Supplier

    99
    PeproTech recombinant human tgf β1
    BP reduced collagen I production in lung fibroblast pre-stimulated with recombinant <t>TGF-β1.</t> TGF-β (5 ng/mL) stimulate for 12 h and ( A ) mRNA and ( B ) protein expression levels of BP treatment in several dosages (0, 10, 20, and 30 µg/mL) for 24 h on type I collagen, and SOX2 expressions. ( C ) mRNA and ( D ) protein expression levels of BP treatment for several time points (0, 1, 3, 6, 12, 24, and 48 h) in the dosage of 30 µg/mL on type I collagen and SOX2 expressions. The same amount of DMSO was added in 0 µg/mL groups as a vehicle control. Data showed 3 independent qPCR experiments and presented are mean ± SD. * denotes a significant decrease with the 0 µg/ml group of p
    Recombinant Human Tgf β1, supplied by PeproTech, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human tgf β1/product/PeproTech
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    recombinant human tgf β1 - by Bioz Stars, 2021-04
    99/100 stars
      Buy from Supplier

    86
    R&D Systems human tgf β1
    Treatment over control for male and female cells cultured on microstructured Ti surfaces and treated with 17β-estradiol for 24 h at confluence on TCPS. Cell number ( a) and alkaline phosphatase-specific activity in cell lysates was assessed ( b ). Production of osteocalcin ( c ), osteoprotegerin ( d ), and active ( e ) and latent <t>TGF-β1</t> ( f ) after 24-h fresh medium incubation. * p
    Human Tgf β1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human tgf β1/product/R&D Systems
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human tgf β1 - by Bioz Stars, 2021-04
    86/100 stars
      Buy from Supplier

    99
    R&D Systems recombinant human tgfβ1
    <t>TGFβ1</t> and miR-133a target ESRP1 pathways in airway epithelial cells. ( a ) Beas-2b cells were treated with 5 ng/ml TGFβ1 for the indicated time. ( b ) Beas-2b and NHBE cells were mock transfected, or transfected with control or miR-133a mimics. Cells were harvested 3 days later for western blot analysis of indicated proteins. Experiments were conducted at least three times, and representative results are shown. The grouped blots in ( a ) were cropped from different parts of the same gel. The anti-p120ctn and anti-GAPDH blots in ( b .
    Recombinant Human Tgfβ1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human tgfβ1/product/R&D Systems
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    recombinant human tgfβ1 - by Bioz Stars, 2021-04
    99/100 stars
      Buy from Supplier





    Image Search Results


    Changes in ROS and GSH levels due to TGF-β1-mediated xCT repression. a PLC/PRF/5 ( n = 6), Huh7 ( n = 3), Huh6 ( n = 3), and HepG2 ( n = 3) cells were treated with either vehicle or 5 ng/mL of TGF-β1 for 24 h and then collected to measure GSH levels. b PLC/PRF/5 cells ( n = 3) transiently transfected with a mock- or Myc-DDK-tagged xCT-expressing vector were treated with vehicle or 5 ng/mL of TGF-β1 for 24 h and then sampled to measure GSH and protein expression levels. c PLC/PRF/5 ( n = 3) and Huh7 ( n = 3 or 6) cells transfected with a mock- or xCT-expressing vector were treated with 5 ng/mL of TGF-β1 for 24 h and then collected for ROS measurement using CM-H 2 DCFDA and western blot analysis. At 1 h before ROS measurement, 30 µM of tBHP was added to stimulate ROS generation in Huh7 cells. Overexpressed xCT was detected as having a higher molecular weight than endogenous xCT in the western blot analyses; multiple analyses are shown as the mean ± SD. * P

    Journal: Cell Death & Disease

    Article Title: TGF-β1-mediated repression of SLC7A11 drives vulnerability to GPX4 inhibition in hepatocellular carcinoma cells

    doi: 10.1038/s41419-020-2618-6

    Figure Lengend Snippet: Changes in ROS and GSH levels due to TGF-β1-mediated xCT repression. a PLC/PRF/5 ( n = 6), Huh7 ( n = 3), Huh6 ( n = 3), and HepG2 ( n = 3) cells were treated with either vehicle or 5 ng/mL of TGF-β1 for 24 h and then collected to measure GSH levels. b PLC/PRF/5 cells ( n = 3) transiently transfected with a mock- or Myc-DDK-tagged xCT-expressing vector were treated with vehicle or 5 ng/mL of TGF-β1 for 24 h and then sampled to measure GSH and protein expression levels. c PLC/PRF/5 ( n = 3) and Huh7 ( n = 3 or 6) cells transfected with a mock- or xCT-expressing vector were treated with 5 ng/mL of TGF-β1 for 24 h and then collected for ROS measurement using CM-H 2 DCFDA and western blot analysis. At 1 h before ROS measurement, 30 µM of tBHP was added to stimulate ROS generation in Huh7 cells. Overexpressed xCT was detected as having a higher molecular weight than endogenous xCT in the western blot analyses; multiple analyses are shown as the mean ± SD. * P

    Article Snippet: Recombinant human TGF-β1 (R & D Systems, Minneapolis, MN, USA) was added to the cultures 18 h after pre-incubation in medium containing 2% FBS; the TGF-β1 and media were replaced every 3 days to prevent depletion if needed.

    Techniques: Planar Chromatography, Transfection, Expressing, Plasmid Preparation, Western Blot, Molecular Weight

    Potentiation of the tBHP-triggered lipid peroxidation by TGF-β1 in PLC/PRF/5 and Huh7 cells. a PLC/PRF/5 ( n = 6) and Huh7 cells ( n = 4) were treated with either vehicle or 5 ng/mL of TGF-β1 for 2 days. At 1 h before the measurement, tBHP was added at doses of 100 µM to PLC/PRF/5 cells ( n = 3) and 50 µM to Huh7 cells ( n = 4)(right). b Cells ( n = 3) were pretreated with 20 µM Fer-1 1 h before TGF-β1 treatment. DFOA was added at doses of 100 µM 1 h before the measurement in PLC/PRF/5 cells or before tBHP treatment in Huh7 cells. TGF-β1 and tBHP were treated as described in a . The first two groups in Huh7 cells (tBHP, TGF-β1 with tBHP) are identical to a as these experiments were performed at once, but displayed again to enhance understanding. c PLC/PRF/5 ( n = 4) and Huh7 cells ( n = 4) were treated with either vehicle or 5 ng/mL TGF-β1 for 8 days. tBHP was added 1 h before measurement at doses of 100 µM in PLC/PRF/5 cells ( n = 4) and 50 µM in Huh7 cells ( n = 4). d SK-Hep1 ( n = 3) and SNU475 ( n = 3) cells were treated with 5 ng/mL of TGF-β1 for 2 days and then further incubated with tBHP at the indicated concentrations for 1 h. Lipid peroxidation was measured with the BODIPY® C11 probe and expressed as the mean fluorescence intensity (MFI); multiple analyses are shown as the mean ± SD. Representative histograms were shown in supplemental Fig. 1 . * P

    Journal: Cell Death & Disease

    Article Title: TGF-β1-mediated repression of SLC7A11 drives vulnerability to GPX4 inhibition in hepatocellular carcinoma cells

    doi: 10.1038/s41419-020-2618-6

    Figure Lengend Snippet: Potentiation of the tBHP-triggered lipid peroxidation by TGF-β1 in PLC/PRF/5 and Huh7 cells. a PLC/PRF/5 ( n = 6) and Huh7 cells ( n = 4) were treated with either vehicle or 5 ng/mL of TGF-β1 for 2 days. At 1 h before the measurement, tBHP was added at doses of 100 µM to PLC/PRF/5 cells ( n = 3) and 50 µM to Huh7 cells ( n = 4)(right). b Cells ( n = 3) were pretreated with 20 µM Fer-1 1 h before TGF-β1 treatment. DFOA was added at doses of 100 µM 1 h before the measurement in PLC/PRF/5 cells or before tBHP treatment in Huh7 cells. TGF-β1 and tBHP were treated as described in a . The first two groups in Huh7 cells (tBHP, TGF-β1 with tBHP) are identical to a as these experiments were performed at once, but displayed again to enhance understanding. c PLC/PRF/5 ( n = 4) and Huh7 cells ( n = 4) were treated with either vehicle or 5 ng/mL TGF-β1 for 8 days. tBHP was added 1 h before measurement at doses of 100 µM in PLC/PRF/5 cells ( n = 4) and 50 µM in Huh7 cells ( n = 4). d SK-Hep1 ( n = 3) and SNU475 ( n = 3) cells were treated with 5 ng/mL of TGF-β1 for 2 days and then further incubated with tBHP at the indicated concentrations for 1 h. Lipid peroxidation was measured with the BODIPY® C11 probe and expressed as the mean fluorescence intensity (MFI); multiple analyses are shown as the mean ± SD. Representative histograms were shown in supplemental Fig. 1 . * P

    Article Snippet: Recombinant human TGF-β1 (R & D Systems, Minneapolis, MN, USA) was added to the cultures 18 h after pre-incubation in medium containing 2% FBS; the TGF-β1 and media were replaced every 3 days to prevent depletion if needed.

    Techniques: Planar Chromatography, Incubation, Fluorescence

    TGF-β1-mediated vulnerability to GPX4 inhibition in PLC/PRF/5 and Huh7 cells. Cells were incubated with vehicle or TGF-β1 (0.03 ng/mL for PLC/PRF/5 cells and 5 ng/mL for Huh7 cells) for 2 days. Then, the cells were exposed to RSL3 in a dose-dependent manner in the presence or absence of TGF-β1 for another 2 days. a Cell viability was measured with the CellTiter Glo® assay, and the CI was calculated following the Chou–Talalay method. 1~5 corresponds to the data for RSL3 dose at 0.01 (1), 0.03 (2), 0.1 (3), 0.3 (4), and 1.0 (5) µM. b Cell images were captured 1 day after treatment with 0.03 µM of RSL3. The cells were stained with 1 µg/mL PI for 20 min and then monitored with the EVOS® cell imaging system.

    Journal: Cell Death & Disease

    Article Title: TGF-β1-mediated repression of SLC7A11 drives vulnerability to GPX4 inhibition in hepatocellular carcinoma cells

    doi: 10.1038/s41419-020-2618-6

    Figure Lengend Snippet: TGF-β1-mediated vulnerability to GPX4 inhibition in PLC/PRF/5 and Huh7 cells. Cells were incubated with vehicle or TGF-β1 (0.03 ng/mL for PLC/PRF/5 cells and 5 ng/mL for Huh7 cells) for 2 days. Then, the cells were exposed to RSL3 in a dose-dependent manner in the presence or absence of TGF-β1 for another 2 days. a Cell viability was measured with the CellTiter Glo® assay, and the CI was calculated following the Chou–Talalay method. 1~5 corresponds to the data for RSL3 dose at 0.01 (1), 0.03 (2), 0.1 (3), 0.3 (4), and 1.0 (5) µM. b Cell images were captured 1 day after treatment with 0.03 µM of RSL3. The cells were stained with 1 µg/mL PI for 20 min and then monitored with the EVOS® cell imaging system.

    Article Snippet: Recombinant human TGF-β1 (R & D Systems, Minneapolis, MN, USA) was added to the cultures 18 h after pre-incubation in medium containing 2% FBS; the TGF-β1 and media were replaced every 3 days to prevent depletion if needed.

    Techniques: Inhibition, Planar Chromatography, Incubation, Glo Assay, Staining, Imaging

    The repression of xCT expression by TGF-β1 in a subset of HCC cell lines. a TGF-β1 was administered to PLC/PRF/5, Huh7, Huh6, HepG2, SNU387, SNU449, SNU475, and SK-Hep1 cells at a concentration of 5 ng/mL and cell viability was measured using the CellTiter Glo® assay after 6 days; three independent experiments were performed in triplicate. b TGF-β1 was applied to PLC/PRF/5 ( n = 4), Huh7 ( n = 3), Huh6 ( n = 4), HepG2 ( n = 4), SNU387 ( n = 3), SNU449 ( n = 3), SNU475 ( n = 3), and SK-Hep1 ( n = 3) cells for 24 or 48 h at a concentration of 5 ng/mL, and then whole-cell lysates were assessed with western blot analyses. Representative images are shown. c PLC/PRF/5 ( n = 5), Huh7 ( n = 7), Huh6 ( n = 3), and HepG2 ( n = 3) cells were treated with 5 ng/mL of TGF-β1 for 24 h and then collected for RT-PCR analyses to detect the mRNA levels of xCT, vimentin, and β-actin; vimentin was used as a positive TGF-β1-responsive gene. All data are expressed as the mean ± SD. * P

    Journal: Cell Death & Disease

    Article Title: TGF-β1-mediated repression of SLC7A11 drives vulnerability to GPX4 inhibition in hepatocellular carcinoma cells

    doi: 10.1038/s41419-020-2618-6

    Figure Lengend Snippet: The repression of xCT expression by TGF-β1 in a subset of HCC cell lines. a TGF-β1 was administered to PLC/PRF/5, Huh7, Huh6, HepG2, SNU387, SNU449, SNU475, and SK-Hep1 cells at a concentration of 5 ng/mL and cell viability was measured using the CellTiter Glo® assay after 6 days; three independent experiments were performed in triplicate. b TGF-β1 was applied to PLC/PRF/5 ( n = 4), Huh7 ( n = 3), Huh6 ( n = 4), HepG2 ( n = 4), SNU387 ( n = 3), SNU449 ( n = 3), SNU475 ( n = 3), and SK-Hep1 ( n = 3) cells for 24 or 48 h at a concentration of 5 ng/mL, and then whole-cell lysates were assessed with western blot analyses. Representative images are shown. c PLC/PRF/5 ( n = 5), Huh7 ( n = 7), Huh6 ( n = 3), and HepG2 ( n = 3) cells were treated with 5 ng/mL of TGF-β1 for 24 h and then collected for RT-PCR analyses to detect the mRNA levels of xCT, vimentin, and β-actin; vimentin was used as a positive TGF-β1-responsive gene. All data are expressed as the mean ± SD. * P

    Article Snippet: Recombinant human TGF-β1 (R & D Systems, Minneapolis, MN, USA) was added to the cultures 18 h after pre-incubation in medium containing 2% FBS; the TGF-β1 and media were replaced every 3 days to prevent depletion if needed.

    Techniques: Expressing, Planar Chromatography, Concentration Assay, Glo Assay, Western Blot, Reverse Transcription Polymerase Chain Reaction

    Time- and dose-dependent repressions of xCT expression by TGF-β1 in PLC/PRF/5 and Huh7 cells. Cells were treated with TGF-β1 at a concentration of 5 ng/mL for 3, 6, 12, or 24 h and sampled for western blot analysis ( a ) or for 18, 24, or 30 h and sampled for RT-PCR analyses ( b ). c TGF-β1 was administered at the concentrations of 0, 0.625, 1.25, 2.5, and 5 ng/mL for 24 h and whole-cell lysates were used for western blot analysis. d PLC/PRF/5 and Huh7 cells treated with 5 ng/mL of TGF-β1 for 24 h were fractionated to obtain plasma membrane and cytosol samples and then used for Western blot analysis. E-cadherin and HSP70 were assessed as marker proteins for the plasma membrane and cytosol fractions, respectively. Representative data from three independent experiments are shown. * P

    Journal: Cell Death & Disease

    Article Title: TGF-β1-mediated repression of SLC7A11 drives vulnerability to GPX4 inhibition in hepatocellular carcinoma cells

    doi: 10.1038/s41419-020-2618-6

    Figure Lengend Snippet: Time- and dose-dependent repressions of xCT expression by TGF-β1 in PLC/PRF/5 and Huh7 cells. Cells were treated with TGF-β1 at a concentration of 5 ng/mL for 3, 6, 12, or 24 h and sampled for western blot analysis ( a ) or for 18, 24, or 30 h and sampled for RT-PCR analyses ( b ). c TGF-β1 was administered at the concentrations of 0, 0.625, 1.25, 2.5, and 5 ng/mL for 24 h and whole-cell lysates were used for western blot analysis. d PLC/PRF/5 and Huh7 cells treated with 5 ng/mL of TGF-β1 for 24 h were fractionated to obtain plasma membrane and cytosol samples and then used for Western blot analysis. E-cadherin and HSP70 were assessed as marker proteins for the plasma membrane and cytosol fractions, respectively. Representative data from three independent experiments are shown. * P

    Article Snippet: Recombinant human TGF-β1 (R & D Systems, Minneapolis, MN, USA) was added to the cultures 18 h after pre-incubation in medium containing 2% FBS; the TGF-β1 and media were replaced every 3 days to prevent depletion if needed.

    Techniques: Expressing, Planar Chromatography, Concentration Assay, Western Blot, Reverse Transcription Polymerase Chain Reaction, Marker

    Non-canonical TGF-β1 signaling pathways involved in the regulation of xCT expression. a PLC/PRF/5 ( n = 5) and Huh7 ( n = 4) cells were pretreated with AZD6244 (0.1 µM for PLC/PRF/5 cells and 1 µM for Huh7 cells), MK2206 (0.1 µM for PLC/PRF/5 cells and 1 µM for Huh7 cells), or BEZ235 (0.01 µM for PLC/PRF/5 cells and 0.1 µM for Huh7 cells) for 1 h and then further incubated with TGF-β1 for 24 h. b PLC/PRF/5 ( n = 3) and Huh7 ( n = 3) cells were pretreated with either SB203580 (5 µM), SP600125 (10 µM), or Y27632 (10 µM) for 1 h and then further incubated with TGF-β1 for 24 h; total cell lysates were used for western blot analysis. Independent experiments are expressed as the mean ± SD; representative images are shown. * P

    Journal: Cell Death & Disease

    Article Title: TGF-β1-mediated repression of SLC7A11 drives vulnerability to GPX4 inhibition in hepatocellular carcinoma cells

    doi: 10.1038/s41419-020-2618-6

    Figure Lengend Snippet: Non-canonical TGF-β1 signaling pathways involved in the regulation of xCT expression. a PLC/PRF/5 ( n = 5) and Huh7 ( n = 4) cells were pretreated with AZD6244 (0.1 µM for PLC/PRF/5 cells and 1 µM for Huh7 cells), MK2206 (0.1 µM for PLC/PRF/5 cells and 1 µM for Huh7 cells), or BEZ235 (0.01 µM for PLC/PRF/5 cells and 0.1 µM for Huh7 cells) for 1 h and then further incubated with TGF-β1 for 24 h. b PLC/PRF/5 ( n = 3) and Huh7 ( n = 3) cells were pretreated with either SB203580 (5 µM), SP600125 (10 µM), or Y27632 (10 µM) for 1 h and then further incubated with TGF-β1 for 24 h; total cell lysates were used for western blot analysis. Independent experiments are expressed as the mean ± SD; representative images are shown. * P

    Article Snippet: Recombinant human TGF-β1 (R & D Systems, Minneapolis, MN, USA) was added to the cultures 18 h after pre-incubation in medium containing 2% FBS; the TGF-β1 and media were replaced every 3 days to prevent depletion if needed.

    Techniques: Expressing, Planar Chromatography, Incubation, Western Blot

    Canonical TGF-β1 signaling pathways involved in the regulation of xCT expression. a PLC/PRF/5 and Huh7 cells were pretreated with 2.5 µM of SB431542 for 1 h and then challenged with 5 ng/mL of TGF-β1 for 24 h ( n = 3). b PLC/PRF/5 and Huh7 cells were transiently transfected with scrambled siRNA or siRNA targeting Smad2 ( n = 4), Smad3 ( n = 3 for PLC/PRF/5 cells and n = 6 for Huh7 cells), or Smad4 ( n = 3) and then exposed to TGF-β1 for 24 h. c Huh7 cells ( n = 3) were transiently transfected with mock- or Smad3-expressing plasmid, recovered overnight, and then further incubated with TGF-β1 for 24 h; total cell lysates were used for the western blot analysis. Data from independent experiments are expressed as the mean ± SD; representative images are shown. * P

    Journal: Cell Death & Disease

    Article Title: TGF-β1-mediated repression of SLC7A11 drives vulnerability to GPX4 inhibition in hepatocellular carcinoma cells

    doi: 10.1038/s41419-020-2618-6

    Figure Lengend Snippet: Canonical TGF-β1 signaling pathways involved in the regulation of xCT expression. a PLC/PRF/5 and Huh7 cells were pretreated with 2.5 µM of SB431542 for 1 h and then challenged with 5 ng/mL of TGF-β1 for 24 h ( n = 3). b PLC/PRF/5 and Huh7 cells were transiently transfected with scrambled siRNA or siRNA targeting Smad2 ( n = 4), Smad3 ( n = 3 for PLC/PRF/5 cells and n = 6 for Huh7 cells), or Smad4 ( n = 3) and then exposed to TGF-β1 for 24 h. c Huh7 cells ( n = 3) were transiently transfected with mock- or Smad3-expressing plasmid, recovered overnight, and then further incubated with TGF-β1 for 24 h; total cell lysates were used for the western blot analysis. Data from independent experiments are expressed as the mean ± SD; representative images are shown. * P

    Article Snippet: Recombinant human TGF-β1 (R & D Systems, Minneapolis, MN, USA) was added to the cultures 18 h after pre-incubation in medium containing 2% FBS; the TGF-β1 and media were replaced every 3 days to prevent depletion if needed.

    Techniques: Expressing, Planar Chromatography, Transfection, Plasmid Preparation, Incubation, Western Blot

    BP reduced collagen I production in lung fibroblast pre-stimulated with recombinant TGF-β1. TGF-β (5 ng/mL) stimulate for 12 h and ( A ) mRNA and ( B ) protein expression levels of BP treatment in several dosages (0, 10, 20, and 30 µg/mL) for 24 h on type I collagen, and SOX2 expressions. ( C ) mRNA and ( D ) protein expression levels of BP treatment for several time points (0, 1, 3, 6, 12, 24, and 48 h) in the dosage of 30 µg/mL on type I collagen and SOX2 expressions. The same amount of DMSO was added in 0 µg/mL groups as a vehicle control. Data showed 3 independent qPCR experiments and presented are mean ± SD. * denotes a significant decrease with the 0 µg/ml group of p

    Journal: International Journal of Molecular Sciences

    Article Title: Non-Canonical Regulation of Type I Collagen through Promoter Binding of SOX2 and Its Contribution to Ameliorating Pulmonary Fibrosis by Butylidenephthalide

    doi: 10.3390/ijms19103024

    Figure Lengend Snippet: BP reduced collagen I production in lung fibroblast pre-stimulated with recombinant TGF-β1. TGF-β (5 ng/mL) stimulate for 12 h and ( A ) mRNA and ( B ) protein expression levels of BP treatment in several dosages (0, 10, 20, and 30 µg/mL) for 24 h on type I collagen, and SOX2 expressions. ( C ) mRNA and ( D ) protein expression levels of BP treatment for several time points (0, 1, 3, 6, 12, 24, and 48 h) in the dosage of 30 µg/mL on type I collagen and SOX2 expressions. The same amount of DMSO was added in 0 µg/mL groups as a vehicle control. Data showed 3 independent qPCR experiments and presented are mean ± SD. * denotes a significant decrease with the 0 µg/ml group of p

    Article Snippet: In vitro studies of lung fibrosis were performed in normal Human lung fibroblast (NHLF), which was stimulated into fibrogenesis by recombinant human TGF-β1 (PeproTech, Catalog Number: 100-21, 5 ng/mL) for 12 h.

    Techniques: Recombinant, Expressing, Real-time Polymerase Chain Reaction

    Treatment over control for male and female cells cultured on microstructured Ti surfaces and treated with 17β-estradiol for 24 h at confluence on TCPS. Cell number ( a) and alkaline phosphatase-specific activity in cell lysates was assessed ( b ). Production of osteocalcin ( c ), osteoprotegerin ( d ), and active ( e ) and latent TGF-β1 ( f ) after 24-h fresh medium incubation. * p

    Journal: Biology of Sex Differences

    Article Title: Human osteoblasts exhibit sexual dimorphism in their response to estrogen on microstructured titanium surfaces

    doi: 10.1186/s13293-018-0190-x

    Figure Lengend Snippet: Treatment over control for male and female cells cultured on microstructured Ti surfaces and treated with 17β-estradiol for 24 h at confluence on TCPS. Cell number ( a) and alkaline phosphatase-specific activity in cell lysates was assessed ( b ). Production of osteocalcin ( c ), osteoprotegerin ( d ), and active ( e ) and latent TGF-β1 ( f ) after 24-h fresh medium incubation. * p

    Article Snippet: Active TGF-β1 was measured prior to acidification of the conditioned media, using an enzyme-linked immunoassay (ELISA) kit specific for human TGF-β1 (TGF-β1 DuoSet, R & D System, Minneapolis, MN).

    Techniques: Cell Culture, Activity Assay, Incubation

    Treatment over control for male and female cells cultured on microstructured Ti surfaces and treated with 1α,25(OH) 2 D 3 for 24 h at confluence on TCPS. Cell number ( a ), and alkaline phosphatase specific activity in cell lysates was assessed ( b ). Production of osteocalcin ( c ), osteoprotegerin ( d ), and active ( e ) and latent TGF-β1 ( f ) after 24-h fresh medium incubation. * p

    Journal: Biology of Sex Differences

    Article Title: Human osteoblasts exhibit sexual dimorphism in their response to estrogen on microstructured titanium surfaces

    doi: 10.1186/s13293-018-0190-x

    Figure Lengend Snippet: Treatment over control for male and female cells cultured on microstructured Ti surfaces and treated with 1α,25(OH) 2 D 3 for 24 h at confluence on TCPS. Cell number ( a ), and alkaline phosphatase specific activity in cell lysates was assessed ( b ). Production of osteocalcin ( c ), osteoprotegerin ( d ), and active ( e ) and latent TGF-β1 ( f ) after 24-h fresh medium incubation. * p

    Article Snippet: Active TGF-β1 was measured prior to acidification of the conditioned media, using an enzyme-linked immunoassay (ELISA) kit specific for human TGF-β1 (TGF-β1 DuoSet, R & D System, Minneapolis, MN).

    Techniques: Cell Culture, Activity Assay, Incubation

    Donor-specific response of male and female cells cultured on microstructured Ti surfaces and treated with 17β-estradiol for 24 h at confluence on TCPS. Cell number was assessed to measure proliferation ( a , f ). Alkaline phosphatase-specific activity in cell lysates was assessed ( b , g ). Production of osteocalcin ( c , h ), osteoprotegerin ( d , i ), and latent TGF-β1 ( e , j ) after 24-h fresh medium incubation. * p

    Journal: Biology of Sex Differences

    Article Title: Human osteoblasts exhibit sexual dimorphism in their response to estrogen on microstructured titanium surfaces

    doi: 10.1186/s13293-018-0190-x

    Figure Lengend Snippet: Donor-specific response of male and female cells cultured on microstructured Ti surfaces and treated with 17β-estradiol for 24 h at confluence on TCPS. Cell number was assessed to measure proliferation ( a , f ). Alkaline phosphatase-specific activity in cell lysates was assessed ( b , g ). Production of osteocalcin ( c , h ), osteoprotegerin ( d , i ), and latent TGF-β1 ( e , j ) after 24-h fresh medium incubation. * p

    Article Snippet: Active TGF-β1 was measured prior to acidification of the conditioned media, using an enzyme-linked immunoassay (ELISA) kit specific for human TGF-β1 (TGF-β1 DuoSet, R & D System, Minneapolis, MN).

    Techniques: Cell Culture, Activity Assay, Incubation

    Response of male and female osteoblasts isolated from human donors to microstructured Ti surfaces (PT, SLA, modSLA). Cell number was assessed to determine proliferation of cells, at confluence on TCPS ( a ). Alkaline phosphatase-specific activity was determined in cell lysates ( b ). Production of osteocalcin ( c) , osteoprotegerin ( d) , and active ( e ) and latent TGF-β1 ( f ) after 24-h fresh medium incubation. * p

    Journal: Biology of Sex Differences

    Article Title: Human osteoblasts exhibit sexual dimorphism in their response to estrogen on microstructured titanium surfaces

    doi: 10.1186/s13293-018-0190-x

    Figure Lengend Snippet: Response of male and female osteoblasts isolated from human donors to microstructured Ti surfaces (PT, SLA, modSLA). Cell number was assessed to determine proliferation of cells, at confluence on TCPS ( a ). Alkaline phosphatase-specific activity was determined in cell lysates ( b ). Production of osteocalcin ( c) , osteoprotegerin ( d) , and active ( e ) and latent TGF-β1 ( f ) after 24-h fresh medium incubation. * p

    Article Snippet: Active TGF-β1 was measured prior to acidification of the conditioned media, using an enzyme-linked immunoassay (ELISA) kit specific for human TGF-β1 (TGF-β1 DuoSet, R & D System, Minneapolis, MN).

    Techniques: Isolation, Activity Assay, Incubation

    TGFβ1 and miR-133a target ESRP1 pathways in airway epithelial cells. ( a ) Beas-2b cells were treated with 5 ng/ml TGFβ1 for the indicated time. ( b ) Beas-2b and NHBE cells were mock transfected, or transfected with control or miR-133a mimics. Cells were harvested 3 days later for western blot analysis of indicated proteins. Experiments were conducted at least three times, and representative results are shown. The grouped blots in ( a ) were cropped from different parts of the same gel. The anti-p120ctn and anti-GAPDH blots in ( b .

    Journal: Scientific Reports

    Article Title: Up-regulated miR-133a orchestrates epithelial-mesenchymal transition of airway epithelial cells

    doi: 10.1038/s41598-018-33913-x

    Figure Lengend Snippet: TGFβ1 and miR-133a target ESRP1 pathways in airway epithelial cells. ( a ) Beas-2b cells were treated with 5 ng/ml TGFβ1 for the indicated time. ( b ) Beas-2b and NHBE cells were mock transfected, or transfected with control or miR-133a mimics. Cells were harvested 3 days later for western blot analysis of indicated proteins. Experiments were conducted at least three times, and representative results are shown. The grouped blots in ( a ) were cropped from different parts of the same gel. The anti-p120ctn and anti-GAPDH blots in ( b .

    Article Snippet: To examine TGFβ1-induced EMT, Beas-2b cells were seeded a day prior in 6 well or 12 well plates, and then stimulated at ~20% confluence without or with 5 ng/ml of recombinant human TGFβ1 (R & D Systems, Minneapolis, MN) in complete BEGM medium.

    Techniques: Transfection, Western Blot